FeesSafety
Pluang+

Thematic ETFs boom in 2026 as fund managers chase new trends beyond AI.

Market News
24 Oct 2026
Market Watch
View Source
Bullish
Thematic ETFs boom in 2026 as fund managers chase new trends beyond AI.

In 2026, thematic ETFs are experiencing rapid growth as fund managers launch new products targeting emerging market themes beyond artificial intelligence. The success of AI-related funds, like the Roundhill Memory ETF focusing on memory stocks, has sparked a surge in thematic investing. This trend reflects investors' eagerness to capitalize on innovations such as robotics and the space economy, signaling a shift toward diversified tech-driven opportunities. The boom in thematic ETFs highlights the evolving landscape of investment strategies seeking the next major market theme.

Thematic ETFs and their rapid growth in 2026 provide context for this market snapshot from Pluang. As of Oct 24, 2026 16:01 WIB, among 150 priced US stocks tradable on Pluang, 46 rose and 102 fell. Notable movers include T (AT&T Inc.) at USD 20.93 with a 1-day change of -7.96% and Pluang order activity of 41% Sell / 59% Buy, SLB (Schlumberger NV) at USD 53.06 with +7.08% and 83% Sell / 17% Buy, and HAL (Halliburton Company) at USD 34.92 with +5.21% and 86% Sell / 14% Buy. Typical hold times range from 89 to 118 days.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
BlackRock TCP Capital remains a sell amid structural challenges despite high dividend yield.

BlackRock TCP Capital remains a sell amid structural challenges despite high dividend yield.

BlackRock TCP Capital (TCPC) continues to face structural issues and sector headwinds, leading to a sell recommendation despite trading at a deep discount to its net asset value (NAV). The company has restructured its portfolio, including a significa...

Market News
Bearish
4 hours ago
Blockstream opens Swiss office to offer Bitcoin infrastructure consulting for European financial firms

Blockstream opens Swiss office to offer Bitcoin infrastructure consulting for European financial firms

Blockstream has opened a new office in Lugano, Switzerland, launching consulting services to help banks and asset managers design and implement Bitcoin infrastructure. The service covers technical planning, system architecture, and integration for pr...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App